Tocilizumab in the treatment of twelve cases with aa amyloidosis secondary to familial mediterranean fever

BACKGROUND: There is no established treatment of AA amyloidosis, a long-term complication of various chronic inflammatory diseases associated with increased mortality, such as familial Mediterranian fever (FMF). Recently there are few reports pointing out that tocilizumab(TCZ), an anti IL-6 agent ma...

Descripción completa

Detalles Bibliográficos
Autores principales: Ugurlu, Serdal, Hacioglu, Aysa, Adibnia, Yasaman, Hamuryudan, Vedat, Ozdogan, Huri
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5450086/
https://www.ncbi.nlm.nih.gov/pubmed/28558744
http://dx.doi.org/10.1186/s13023-017-0642-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5450086/
https://www.ncbi.nlm.nih.gov/pubmed/28558744
http://dx.doi.org/10.1186/s13023-017-0642-0

Ejemplares similares